Daniel A. Heller, PhD

Lab Head
Daniel A. Heller, PhD

Office Phone


Lab Phone


Dr. Daniel A. Heller, PhD, is Head of the Cancer Nanomedicine Laboratory, Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chair, an Associate Member in the Molecular Pharmacology Program at Memorial Sloan-Kettering Cancer Center, and an Associate Professor in the Department of Pharmacology at Weill Cornell Medicine of Cornell University. His laboratory  focuses on the development of nanoscale technologies for the treatment, diagnosis, and research of cancer. Dr. Heller obtained his Bachelor’s degree in History from Rice University in 2000 and PhD in chemistry from the University of Illinois at Urbana-Champaign in 2010, working in the laboratory of Michael Strano.  He completed a Damon Runyon Cancer Research Foundation Postdoctoral Fellowship in the laboratory of Robert Langer at the David H. Koch Institute for Integrative Cancer Research at MIT in 2012. He is a 2012 recipient of the National Institutes of Health Director’s New Innovator Award, a 2015 Kavli Fellow, a 2017 recipient of the Pershing Square Sohn Prize for Young Investigators in Cancer Research, a 2018 American Cancer Society Research Scholar, a 2018 NSF CAREER Awardee, a 2018 recipient of the CRS Nanomedicine and Nanoscale Drug Delivery Focus Group Junior Faculty Award, the 2020 Pharmacology Teaching and Mentoring Awardee from Weill Cornell Graduate School, and a 2021 American Institute for Medical and Biological Engineering (AIMBE) Fellow.

View a full listing of Daniel A. Heller’s journal articles.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Daniel A. Heller discloses the following relationships and financial interests:

  • Concarlo Holdings, LLC
    Provision of Services
  • Goldilocks Therapeutics Inc.
    Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services
  • Lime Therapeutics, Inc.
    Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services (uncompensated)
  • Mediphage Bioceuticals, Inc.
    Ownership / Equity Interests; Provision of Services (uncompensated)
  • Nanorobotics, Inc.
    Ownership / Equity Interests
  • Nirova BioSense, Inc.
    Ownership / Equity Interests
  • Resident Diagnostics, Inc.
    Ownership / Equity Interests; Provision of Services (uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures